FRA:SMZ1 (Hong Kong)
Â
Business Description
Sino Biopharmaceutical Ltd
NAICS : 325412
Description
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.3 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.4 | |||||
| Debt-to-EBITDA | 1 | |||||
| Interest Coverage | 13.67 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.62 | |||||
| Beneish M-Score | -1.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.1 | |||||
| 3-Year EBITDA Growth Rate | 17.3 | |||||
| 3-Year EPS without NRI Growth Rate | 17.4 | |||||
| 3-Year FCF Growth Rate | 1.9 | |||||
| 3-Year Book Growth Rate | 36 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -19.94 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.51 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.65 | |||||
| 9-Day RSI | 42.95 | |||||
| 14-Day RSI | 45.65 | |||||
| 6-1 Month Momentum % | 3.71 | |||||
| 12-1 Month Momentum % | -9.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.55 | |||||
| Quick Ratio | 1.42 | |||||
| Cash Ratio | 0.96 | |||||
| Days Inventory | 127.96 | |||||
| Days Sales Outstanding | 58.48 | |||||
| Days Payable | 131.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.46 | |||||
| Dividend Payout Ratio | 0.13 | |||||
| 3-Year Dividend Growth Rate | -2.1 | |||||
| Forward Dividend Yield % | 2.87 | |||||
| 5-Year Yield-on-Cost % | 4.28 | |||||
| 3-Year Average Share Buyback Ratio | 0.1 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.99 | |||||
| Operating Margin % | 16.14 | |||||
| Net Margin % | 29.45 | |||||
| ROE % | 28.64 | |||||
| ROA % | 13.42 | |||||
| ROIC % | 9.27 | |||||
| ROC (Joel Greenblatt) % | 118.72 | |||||
| ROCE % | 25.41 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.82 | |||||
| Forward PE Ratio | 20 | |||||
| PE Ratio without NRI | 10.36 | |||||
| Shiller PE Ratio | 19.53 | |||||
| Price-to-Owner-Earnings | 5.35 | |||||
| PEG Ratio | 0.37 | |||||
| PS Ratio | 2.71 | |||||
| PB Ratio | 2.47 | |||||
| Price-to-Tangible-Book | 2.58 | |||||
| Price-to-Free-Cash-Flow | 14.88 | |||||
| Price-to-Operating-Cash-Flow | 10.71 | |||||
| EV-to-EBIT | 5.9 | |||||
| EV-to-Forward-EBIT | 12.05 | |||||
| EV-to-EBITDA | 5.9 | |||||
| EV-to-Forward-EBITDA | 9.9 | |||||
| EV-to-Revenue | 2.52 | |||||
| EV-to-Forward-Revenue | 2.29 | |||||
| EV-to-FCF | 14.69 | |||||
| Price-to-Projected-FCF | 1.15 | |||||
| Price-to-DCF (Earnings Based) | 0.15 | |||||
| Price-to-DCF (FCF Based) | 0.48 | |||||
| Price-to-Median-PS-Value | 0.74 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.2 | |||||
| Price-to-Graham-Number | 1.06 | |||||
| Earnings Yield (Greenblatt) % | 16.93 | |||||
| Forward Rate of Return (Yacktman) % | 23.94 |
